Jay Tibbitts
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Radiopharmaceutical Chemistry and Applications, CAR-T cell therapy research, Click Chemistry and Applications
Most-Cited Works
- → Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates(2012)980 cited
- → Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer(2010)591 cited
- → Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer(2010)290 cited
- → Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development(2015)205 cited
- → Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats(2011)202 cited
- → The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates(2012)192 cited
- → Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability(2013)190 cited
- → Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism(2012)135 cited
- → Pharmacokinetic Considerations for Antibody Drug Conjugates(2012)132 cited
- → Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response(2012)130 cited